Objective
According to the WHO Osteoarthritis (OA) is one major course of years lived with disability in the elderly and considered a high burden disease, which makes it a research priority in Europe. There is no cure for OA and SoA treatments need to be reconsidered. Current pharmacological interventions consist of analgesic, anti-inflammatory drugs as well as intraarticular steroids and hyaluronic acid (IA-HA) with moderate efficacy and associated long-term side effects. New medications are thus needed both to alleviate pain and slow down disease progression. Taking advantage of the explosion of RNA technologies in the last years, SINPAIN aims to develop a pipeline of siRNA-based therapy built on the combination of current technologies (dyanmic IA-HA and nanocarriers) that will be designed step-by-step in order to reach a successful management of inflammation and innervation therapy for the treatment of early (grade 0-1) and later stages (grade 3-4) of knee osteoarthritis (OA). To do so, a nanoformulation composed of functional IA-HA that can be loaded with vectors, for the delivery of siRNA targeting IL1? and NGF, and nanocarriers will be developed. In parallel, large effort will focus on understanding the pathological mechanisms of OA. To validate efficacy in relevant potency assays, 3D coculture models will be developed with human cells and tested in unique bioreactors mimicking joint environment and biomechanics. With the identified cell targets, IA-HA will be modified with immunomodulator peptide which will activate the adaptive immune response, responsible for OA regeneration. The 4 pipeline products of SINPAIN will be validated in vivo in a relevant OA model with SoA techniques that will demonstrate the reduced inflammation and pain, as well as the cartilage regeneration for the last product. Taking advantage of all the data obtained during the project, a decision-making tool based on machine learning will be validated to offer patients a personalized therapy.
Fields of science
- engineering and technologyenvironmental biotechnologybioremediationbioreactors
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesbasic medicineimmunology
- medical and health sciencesmedical biotechnologynanomedicine
- natural sciencescomputer and information sciencesartificial intelligencemachine learning
Programme(s)
Funding Scheme
HORIZON-AG - HORIZON Action Grant Budget-BasedCoordinator
20014 San Sebastian
Spain
See on map
Participants (9)
13288 Marseille
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
66123 Saarbrucken
See on map
08014 Barcelona
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
4200-135 Porto
See on map
13100 Vercelli
See on map
66386 St Ingbert
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
102 Reykjavik
See on map
94607 Oakland Ca
See on map
75654 Paris
See on map